Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,762 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sample testing Clear all
Recruiting Phase 1 Interventional

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

NCT06606990
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Pidnarulex
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Unidos Contra el VPH

NCT06825689
View directory record Official record
Conditions
Human Papilloma Virus (HPV), Cervical Cancers
Interventions
Self-sampling with urine, Self-sampling with swab, In-clinic Pap/HPV co-testing
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
735 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

NCT06408220
View directory record Official record
Conditions
Gastric Carcinoma
Interventions
Biopsy, Biospecimen Collection, Breath Test, Esophagogastroduodenoscopy, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Phase 3 Interventional

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
158
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Active, not recruiting Early Phase 1 Interventional

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

NCT05333874
View directory record Official record
Conditions
Breast Cancer, Early-Onset
Interventions
Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)

NCT03031418
View directory record Official record
Conditions
Cancer of Prostate
Interventions
ExoDx Prostate Intelliscore
Diagnostic Test
Lead sponsor
Exosome Diagnostics, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
532 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
18
States / cities
Fort Myers, Florida • Miami, Florida • Macon, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 23, 2026, 6:27 PM EDT
Completed Not applicable Interventional

Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)

NCT00566423
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Blood draw
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 23, 2026, 6:27 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

NCT04840979
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176, 18F-florbetaben
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Phase 2 Interventional

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

NCT07140679
View directory record Official record
Conditions
Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Questionnaire Administration, Toripalimab
Procedure · Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Completed No phase listed Observational

Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer

NCT05035615
View directory record Official record
Conditions
Acute Leukemia
Interventions
IUO Acute Leukemia Panel
Diagnostic Test
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
3 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 23, 2026, 6:27 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

NCT06390826
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Sunitinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

NCT06306638
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Endobronchial Ultrasound Bronchoscopy, Interstitial Photodynamic Therapy, Palliative Radiation Therapy, Physical Performance Testing, Questionnaire Administration, Verteporfin, Laser: ML7710-PDT
Procedure · Radiation · Other + 2 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Buffalo, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Panc CA Risk Model & Biomarker Testing In High-Risk Cohort

NCT05287347
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Blood Specimen
Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 23, 2026, 6:27 PM EDT
Completed Not applicable Interventional

Effect of Physiologic Insulin Administration on Cognition

NCT06424652
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Blood draws, Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test, Resting Metabolic Rate (RMR)
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
65 Years to 75 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 23, 2026, 6:27 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

NCT04548752
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
533
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 340 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Phase 3 Interventional

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

NCT07578116
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
59
States / cities
Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing COVID-19 Testing in Chicago's African American Testing Desserts

NCT05197452
View directory record Official record
Conditions
COVID-19 Pandemic
Interventions
COVID-19 Testing
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
Not listed
Enrollment
2,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Phase 1 Interventional

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

NCT05711615
View directory record Official record
Conditions
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Myxofibrosarcoma, Unresectable Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

PICS: Subtitle Cardiac Dysfunction in Older Sepsis Survivors

NCT02276417
View directory record Official record
Conditions
Sepsis
Interventions
Blood Collection, Urine collection, Bioimpedance Analysis, Cognitive Function Tests, Quality-of-life Questionnaires, Physical Function Tests
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Guided Metabolic Detox Program

NCT06061289
View directory record Official record
Conditions
Detoxification Response
Interventions
SP Detox Program
Dietary Supplement
Lead sponsor
Standard Process Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 23, 2026, 6:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors

NCT03304587
View directory record Official record
Conditions
Breast Cancer
Interventions
Polysomnography (PSG), Rectal thermistor 400 Series, Bright blue-green light, Dim red light, Digital foot candle datalogging light meter, Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue, Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance, Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression, Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function, Pittsburgh Sleep Quality Index (PSQI), Center for Epidemiological Studies - Depression, Montreal Cognitive Assessment (MoCA), European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30), Daily Log
Diagnostic Test · Other
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 23, 2026, 6:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients

NCT05716477
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Biospecimen Collection, Survey Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Identifying and Caring for Individuals With Inherited Cancer Syndrome

NCT04494945
View directory record Official record
Conditions
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ, Hematopoietic and Lymphoid System Neoplasm, Hereditary Neoplastic Syndrome, Lynch Syndrome, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Genetic Counseling, Genetic Testing, Survey Administration
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Phase 2 Interventional

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

NCT04840602
View directory record Official record
Conditions
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Positron Emission Tomography, Rituximab, Venetoclax, Zanubrutinib
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
145
States / cities
Tucson, Arizona • Irvine, California • Coral Gables, Florida + 108 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 6:27 PM EDT